Literature DB >> 15133473

Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.

Joan H Admirand1, George Z Rassidakis, Lynne V Abruzzo, Jose R Valbuena, Dan Jones, L Jeffrey Medeiros.   

Abstract

Using immunohistochemical methods, we evaluated zeta-associated protein (ZAP)-70 expression in 341 cases of non-Hodgkin and Hodgkin lymphoma. In B-cell NHL, ZAP-70 was positive in five of six (83%) precursor B-lymphoblastic lymphoma, 11 of 37 (30%) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), five of 39 (13%) mantle cell lymphoma, one of 12 (8%) Burkitt lymphoma, and one of 12 (8%) nodal marginal zone B-cell lymphoma. In 22 cases of CLL/SLL, seven of nine (78%) with unmutated IgVH genes expressed ZAP-70, compared with one of 13 (8%) with mutated IgVH genes (P=0.0015 Fisher's exact test). ZAP-70 expression was not detected in diffuse large B-cell lymphoma (n=26), extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (n=24), follicular lymphoma (n=21), plasma cell myeloma/plasmacytoma (n=10), lymphoplasmacytic lymphoma (n=10), or splenic marginal zone lymphoma (n=6). In T/NK-cell NHL, ZAP-70 was positive in all extranodal natural killer (NK) / T-cell lymphoma, nasal-type (n=6) and enteropathy-type T-cell lymphoma (n=4), four of five (80%) subcutaneous panniculitis-like T-cell lymphoma, six of eight (75%) mycosis fungoides, three of five (60%) precursor T-lymphoblastic lymphoma, 10 of 17 (59%) peripheral T-cell lymphoma, two of four (50%) blastic NK-cell lymphoma, one of three (33%) T-cell prolymphocytic leukemia, 13 of 52 (25%) anaplastic large cell lymphoma, and one of six (17%) angioimmunoblastic T-cell lymphoma. Seven of 12 (58%) cutaneous CD30-positive lymphoproliferative disorders were also ZAP-70-positive. In Hodgkin lymphoma, ZAP-70 was negative in neoplastic cells in all cases tested. ZAP-70 staining in B-cell lymphomas and reactive T cells was predominantly nuclear with variable cytoplasmic staining. By contrast, ZAP-70 staining in T/NK-cell lymphomas was heterogeneous, and a shift from predominantly nuclear to predominantly cytoplasmic staining was observed, particularly in those neoplasms with high-grade morphology. In summary, ZAP-70 is expressed by many lymphoma types, correlates with immunoglobulin heavy-chain variable region gene mutational status in CLL/SLL, and can be detected reliably using immunohistochemical methods.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133473     DOI: 10.1038/modpathol.3800145

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

Review 1.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology.

Authors:  Lynne V Abruzzo; Lynn L Barron; Keith Anderson; Rachel J Newman; William G Wierda; Susan O'brien; Alessandra Ferrajoli; Madan Luthra; Sameer Talwalkar; Rajyalakshmi Luthra; Dan Jones; Michael J Keating; Kevin R Coombes
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

Review 3.  Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.

Authors:  Scott D Boyd; Yasodha Natkunam; John R Allen; Roger A Warnke
Journal:  Appl Immunohistochem Mol Morphol       Date:  2013-03

4.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.

Authors:  Wee J Chng; Roelandt F Schop; Tammy Price-Troska; Irene Ghobrial; Neil Kay; Diane F Jelinek; Morie A Gertz; Angela Dispenzieri; Martha Lacy; Robert A Kyle; Philip R Greipp; Renee C Tschumper; Rafael Fonseca; Peter Leif Bergsagel
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

5.  B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.

Authors:  Elena Sabattini; Rocio Orduz; Cristina Campidelli; Pier Luigi Zinzani; Vincenzo Callea; Simona Zupo; Giovanna Cutrona; Fortunato Morabito; Manlio Ferrarini; Stefano Pileri
Journal:  J Clin Pathol       Date:  2006-08-17       Impact factor: 3.411

6.  Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.

Authors:  William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Guillermo Garcia-Manero; Jorge Cortes; Deborah Thomas; Charles A Koller; Jan A Burger; Susan Lerner; Ellen Schlette; Lynne Abruzzo; Hagop M Kantarjian; Michael J Keating
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

7.  LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.

Authors:  Hatice Duzkale; Carmen D Schweighofer; Kevin R Coombes; Lynn L Barron; Alessandra Ferrajoli; Susan O'Brien; William G Wierda; John Pfeifer; Tadeusz Majewski; Bogdan A Czerniak; Jeffrey L Jorgensen; L Jeffrey Medeiros; Emil J Freireich; Michael J Keating; Lynne V Abruzzo
Journal:  Blood       Date:  2011-02-10       Impact factor: 22.113

8.  Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.

Authors:  Joan H Admirand; Ronald J Knoblock; Kevin R Coombes; Constantine Tam; Ellen J Schlette; William G Wierda; Alessandra Ferrajoli; Susan O'Brien; Michael J Keating; Rajyalakshmi Luthra; L Jeffrey Medeiros; Lynne V Abruzzo
Journal:  Mod Pathol       Date:  2010-07-23       Impact factor: 7.842

9.  p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.

Authors:  Ellen J Schlette; Joan Admirand; William Wierda; Lynne Abruzzo; Katherine I Lin; Susan O'Brien; Susan Lerner; Michael J Keating; Constantine Tam
Journal:  Leuk Lymphoma       Date:  2009-10

10.  Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion.

Authors:  Wenbin Xiao; Wayne W Chen; Lynn Sorbara; Theresa Davies-Hill; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Hum Pathol       Date:  2016-05-14       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.